Mercury Systems, Inc. (MRCY)’s President and CEO Mark Aslett Unloaded 9600 shares of the Company; 7 Bullish Analysts Covering Ardelyx, Inc. (ARDX)

Among 7 analysts covering Ardelyx Inc (NASDAQ:ARDX), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ardelyx Inc had 15 analyst reports since August 18, 2015 according to SRatingsIntel. The stock of Ardelyx, Inc. (NASDAQ:ARDX) earned “Buy” rating by Citigroup on Wednesday, August 10. The stock of Ardelyx, Inc. (NASDAQ:ARDX) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. Citigroup maintained the stock with “Buy” rating in Friday, October 13 report. The stock has “Buy” rating by Wedbush on Thursday, October 12. The stock of Ardelyx, Inc. (NASDAQ:ARDX) earned “Buy” rating by Cantor Fitzgerald on Wednesday, May 31. On Wednesday, August 9 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The stock of Ardelyx, Inc. (NASDAQ:ARDX) has “Buy” rating given on Friday, October 13 by BTIG Research. The firm has “Overweight” rating given on Thursday, October 12 by Cantor Fitzgerald. The stock of Ardelyx, Inc. (NASDAQ:ARDX) earned “Buy” rating by Wedbush on Thursday, September 3. The stock has “Buy” rating by BTIG Research on Tuesday, September 22. See Ardelyx, Inc. (NASDAQ:ARDX) latest ratings:

17/10/2017 Broker: Leerink Swann Rating: Buy New Target: $13.0
13/10/2017 Broker: BTIG Research Rating: Buy New Target: $15.0 Maintain
13/10/2017 Broker: Citigroup Rating: Buy Old Target: $14 New Target: $19 Maintain
12/10/2017 Broker: Wedbush Rating: Buy New Target: $16.0 Maintain
12/10/2017 Broker: Cantor Fitzgerald Rating: Overweight Old Target: $12 New Target: $14 Maintain

Based on an average market price per share of $47.1, Mark Aslett, the Mercury Systems Inc’s President and CEO unloaded 9,600 shares of Mercury Systems Inc worth $452,584 USD. Mark is trying to silently decrease his company’s share, same as he did in the last 30 days. He unloaded another 19,200 shares worth $888,398 USD. Mark Aslett owns precisely 0.93% of Mercury Systems Inc’s market cap or 447,382 shares. The provided info is as revealed in a SEC 4F filing dated March 01, 2018.

The stock decreased 0.04% or $0.02 during the last trading session, reaching $45.95. About 390,257 shares traded or 1.67% up from the average. Mercury Systems, Inc. (NASDAQ:MRCY) has risen 91.74% since March 2, 2017 and is uptrending. It has outperformed by 75.04% the S&P500.

Since September 11, 2017, it had 0 buys, and 12 insider sales for $3.06 million activity. ASLETT MARK sold $461,774 worth of stock or 9,600 shares. HAINES GERALD M II also sold $129,850 worth of Mercury Systems, Inc. (NASDAQ:MRCY) shares. THIBAUD DIDIER M C also sold $176,750 worth of Mercury Systems, Inc. (NASDAQ:MRCY) shares.

Investors sentiment increased to 1.13 in 2017 Q3. Its up 0.12, from 1.01 in 2017Q2. It increased, as 13 investors sold Mercury Systems, Inc. shares while 67 reduced holdings. 33 funds opened positions while 57 raised stakes. 45.09 million shares or 0.45% less from 45.29 million shares in 2017Q2 were reported. Piedmont Inv Advisors Limited Liability Corporation holds 10,479 shares. Thompson Davis & Incorporated accumulated 250 shares or 0.02% of the stock. Barclays Public Limited Com owns 1,187 shares or 0% of their US portfolio. Tudor Invest Et Al has invested 0.01% in Mercury Systems, Inc. (NASDAQ:MRCY). Arizona State Retirement Systems invested in 0.02% or 24,975 shares. 35,500 were accumulated by Teton. Rainier Inv Mngmt Lc owns 1.3% invested in Mercury Systems, Inc. (NASDAQ:MRCY) for 106,770 shares. Guggenheim Limited Co reported 0.01% of its portfolio in Mercury Systems, Inc. (NASDAQ:MRCY). Sg Americas Secs Limited Liability owns 24,155 shares. Tower Capital Lc (Trc) accumulated 4,915 shares. Greenwood Cap Ltd Llc reported 11,982 shares stake. Campbell Adviser Lc has 0.33% invested in Mercury Systems, Inc. (NASDAQ:MRCY). Rk Capital Management Lc invested 2.07% of its portfolio in Mercury Systems, Inc. (NASDAQ:MRCY). King Luther Capital has invested 0.06% in Mercury Systems, Inc. (NASDAQ:MRCY). Dimensional Fund Advisors L P holds 0.04% of its portfolio in Mercury Systems, Inc. (NASDAQ:MRCY) for 1.86 million shares.

Among 9 analysts covering Mercury (NASDAQ:MRCY), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Mercury has $61.0 highest and $19.0 lowest target. $50’s average target is 8.81% above currents $45.95 stock price. Mercury had 23 analyst reports since August 25, 2015 according to SRatingsIntel. The stock has “Buy” rating by Drexel Hamilton on Tuesday, August 25. The rating was maintained by Noble Financial with “Hold” on Wednesday, August 2. The company was initiated on Friday, June 10 by Citigroup. Jefferies maintained Mercury Systems, Inc. (NASDAQ:MRCY) on Monday, January 8 with “Hold” rating. The stock has “Buy” rating by Bank of America on Thursday, February 8. SunTrust maintained Mercury Systems, Inc. (NASDAQ:MRCY) rating on Wednesday, October 18. SunTrust has “Buy” rating and $56.0 target. As per Wednesday, October 25, the company rating was maintained by Noble Financial. As per Thursday, January 19, the company rating was initiated by Suntrust Robinson. The company was initiated on Thursday, January 19 by SunTrust. On Tuesday, January 24 the stock rating was upgraded by Bank of America to “Buy”.

Analysts await Mercury Systems, Inc. (NASDAQ:MRCY) to report earnings on April, 24. They expect $0.27 EPS, up 68.75% or $0.11 from last year’s $0.16 per share. MRCY’s profit will be $13.03 million for 42.55 P/E if the $0.27 EPS becomes a reality. After $0.17 actual EPS reported by Mercury Systems, Inc. for the previous quarter, Wall Street now forecasts 58.82% EPS growth.

Mercury Systems, Inc. provides sensor and safety critical mission processing subsystems for various critical defense and intelligence programs in the United States. The company has market cap of $2.22 billion. The companyÂ’s products and solutions are deployed in approximately 300 programs with 25 defense prime contractors. It has a 50.22 P/E ratio. The Company’s principal programs include Aegis, Patriot, Surface Electronic Warfare Improvement Program, Gorgon Stare, Predator, F-35, Reaper, F-16 SABR, E2D Hawkeye, and Paveway.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. The company has market cap of $254.31 million. The Company’s lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It currently has negative earnings. The firm is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications.